Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources.

ABSTRACT:

Introduction

In addition to significant morbidity and mortality, the coronavirus disease (COVID-19) has strained health care systems globally. This study investigated the cost-effectiveness of remdesivir + standard of care (SOC) for hospitalized COVID-19 patients in the USA.

Methods

This cost-effectiveness analysis considered direct and indirect costs of remdesivir + SOC versus SOC alone among hospitalized COVID-19 patients in the US. Patients entered the model stratified according to their baseline ordinal score. At day 15, patients could transition to another health state, and on day 29, they were assumed to have either died or been discharged. Patients were then followed over a 1-year time horizon, where they could transition to death or be rehospitalized.

Results

SUBMITTER: Barnieh L 

PROVIDER: S-EPMC10206585 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature